Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GliSODin (Centre Hospitalier Universitaire de Nice)
- Development stage
- Unknown
- Lead developer
- Isocell
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
GliSODin is an oral nutraceutical supplement composed of a melon-derived superoxide dismutase (SOD) enzyme combined with gliadin, a wheat protein. The gliadin component serves as a protective carrier, preventing the degradation of SOD by gastric acid and allowing its absorption in the small intestine. As a potent antioxidant, SOD works to neutralize reactive oxygen species and restore antioxidant balance, which is hypothesized to play a role in the pathophysiology of melasma. The Centre Hospitalier Universitaire de Nice conducted a randomized, placebo-controlled trial (NCT03878433) evaluating GliSODin (500 mg/day) in combination with sunscreen for the treatment of melasma severity. The study aimed to leverage SOD's ability to mitigate oxidative stress-induced melanogenesis.
- Brand names
- GliSODinGliSODin Skin BrighteningGliSODin Anti-Aging
- Other names
- SOD-gliadinSuperoxide dismutase-gliadin complex
02
Targets
Misfolded SOD1
Beyond the preview
Go deeper on GliSODin (Centre Hospitalier Universitaire de Nice).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GliSODin (Centre Hospitalier Universitaire de Nice).